Trio Testing: What It Is and When to Consider It

📍Key Takeaways

• Trio testing sequences the proband together with both parents and analyzes them jointly, in contrast to singleton testing, which examines the proband alone.
• The strength of the trio approach lies in the accuracy and efficiency of variant interpretation. It confirms de novo variants immediately, establishes the phase of compound heterozygous variants, and reduces variants of uncertain significance (VUS).
• Priority candidates include sporadic, severe developmental delay or intellectual disability without a clear family history, multiple congenital anomalies, and early-onset presentations, provided parental samples are available.

---

What Trio Testing Is

Whole exome sequencing (WES) and whole genome sequencing (WGS) can be performed as a trio, which includes samples from the proband together with both parents. In the trio approach, each variant detected in the proband is compared directly against the genotypes of both parents. This single comparison changes the nature of variant interpretation.

When a variant is detected on singleton testing, whether it was inherited from a parent or arose anew must be confirmed separately, through sequential parental testing. A trio provides this information from the outset.

Why the Trio Approach Helps

First, the immediate and definitive determination of de novo variants. When a variant is absent in both parents, it is classified as de novo. De novo variants are a major cause of severe developmental disorders: in a large cohort study, an estimated 42% of individuals with severe, undiagnosed developmental disorders carried pathogenic de novo variants in protein-coding regions. In sporadic cases without a family history, this determination becomes a central line of diagnostic evidence.

Second, resolving the phase of compound heterozygous variants. In autosomal recessive disease, whether two variants are inherited from different parents and lie on opposite alleles (in trans) or sit on the same allele (in cis) determines their pathogenic significance. A trio establishes this phase without requiring additional samples.

Third, VUS can be reduced and reclassified. Once de novo status is confirmed through parental comparison, it serves as evidence of pathogenicity under the ACMG/AMP framework (PS2/PM6). Under current standards, the ClinGen SVI point-based recommendation determines the strength of this evidence by integrating confirmation of parental relationships, phenotypic consistency, and the number of de novo observations. With this added evidence, a variant that would have remained a VUS on singleton testing may be upgraded.

Fourth, efficiency of interpretation. Trio data allow benign polymorphisms inherited from the parents to be excluded early, reducing the number of variants that require curation. In severe cases where management decisions are time-sensitive, this efficiency carries clinical weight.

When to Consider a Trio

Trio testing is a priority consideration in the following situations:

• Sporadic, severe developmental delay or intellectual disability without a clear family history
• Syndromic presentations with multiple congenital anomalies
• Marked phenotypic heterogeneity, where candidate genes are difficult to narrow

The advantages of the trio approach are most pronounced in developmental disorders, where the de novo contribution is substantial.

What a Diagnosis Changes

When a de novo variant is confirmed by trio testing, the basis for recurrence-risk counseling becomes clearer. Sporadic de novo variants generally carry a low sibling recurrence risk, though the possibility of parental germline mosaicism should be discussed. A confirmed diagnosis informs family planning, prognostic counseling, and, for some conditions, changes in clinical management.

---

If you are weighing which approach — singleton (proband only), duo, or trio — is the right fit, click the button below to consult directly with 3billion. Our specialists will respond promptly.

---

References

1. McRae JF, Clayton S, Fitzgerald TW, et al.; Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542(7642):433-438. doi:10.1038/nature21062. PMID: 28135719.
2. ClinGen Sequence Variant Interpretation (SVI) Working Group. Recommendation for de novo PS2 and PM6 ACMG/AMP criteria (Version 1.1). Clinical Genome Resource. https://www.clinicalgenome.org/working-groups/sequence-variant-interpretation/
3. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and the AMP. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30.